About Acrux

Acrux is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin, both topically and transdermally.
Acrux is currently developing new transdermal and topical products using a new and novel delivery technology platform.

TECHNOLOGY PROFILE
Acrux's unique products are fast-drying, invisible sprays and liquids which are applied to the skin, delivering the medicine either locally into the tissues or transdermally into the bloodstream. Each product is designed to be preferred by patients over current therapies. The delivery technology is covered by broad, well-differentiated issued patents.
Acrux is developing its own products but also collaborates with companies on early stage product opportunities that fit the Acrux business model. Acrux works closely with corporate partners that are fully capable and committed to further development, and marketing of its products in territories that have not yet been partnered. While the partner will typically be expected to be responsible for manufacturing, marketing, and sales, Acrux is open to alternative approaches to complete remaining development activities.

website icon
Website
employees icon
Employees
industry icon
Industry
Pharmaceutical Manufacturing
location icon
Headquarter
103-113 Stanley St,Melbourne,VIC,AU
description icon
Founded
1998

Acrux Alternatives

Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals

Frequently Asked Questions about Acrux

Who is the CEO of Acrux?

Raviteja Koppalli is the CEO of Acrux. To contact Raviteja Koppalli email at [email protected] or [email protected].

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.

Discover the source of our data

Learn more